Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1105-1112

  Björkhem Bergman, Linda ^a   Acimovic, Jure ^b   Torndal, Ulla Britta ^a   Parini, Paolo ^a   Eriksson, Lennart C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Carcinogenesis; Hepatocarcinogenesis; HMGCoA reductase inhibitors; Liver neoplasm; Mevalonate pathway; Statins; Ubiquinone

Indexed keywords

CHOLESTEROL; LATHOSTEROL; MEVALONIC ACID; MEVINOLIN; UBIQUINONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; LIVER CANCER; LIVER NODULE; LIVER TUMOR; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BODY WEIGHT; CELL GROWTH PROCESSES; CHOLESTEROL; DISEASE MODELS, ANIMAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; LOVASTATIN; MALE; MEVALONIC ACID; ORGAN SIZE; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; UBIQUINONE;

EID: 77953731785     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934): 1383-1389, 1994.
2. Khurana V, Bejjanki HR, Caldito G and Owens MW: Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131(5): 1282-1288, 2007. (Pubitemid 46762329)
3. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC and Giovannucci E: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98(24): 1819-1825, 2006.
4. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK and Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 352(21): 2184-2192, 2005.
5. Coogan PF, Smith J and Rosenberg L: Statin use and risk of colorectal cancer. J Natl Cancer Inst 99(1): 32-40, 2007.
6. Dale KM, Coleman CI, Henyan NN, Kluger J and White CM: Statins and cancer risk: a meta-analysis. JAMA 295(1): 74-80, 2006.
7. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y and Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84(7): 886-891, 2001.
8. Graf H, Jungst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, Reiser M, Waggershauser T, Helmberger T, Walter A, Walli A, Seidel D, Goke B and Jungst D: Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 78(1): 34-38, 2008.
9. Solomon KR and Freeman MR: Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19(4): 113-121, 2008.
10. Sassano A and Platanias LC: Statins in tumor suppression. Cancer Lett 260(1-2): 11-19, 2008.
11. Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D and Scherubl H: Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 43(5): 808-816, 2005.
12. Tatsuta M, Iishi H, Baba M, Iseki K, Yano H, Uehara H, Yamamoto R and Nakaizumi A: Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer 77(4): 581-587, 1998. (Pubitemid 28059465)
13. Herrero-Martin G and Lopez-Rivas A: Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins. FEBS Lett 582(17): 2589-2594, 2008.
14. Eriksson LC and Andersson GN: Membrane biochemistry and chemical hepatocarcinogenesis. Crit Rev Biochem Mol Biol 27(1-2): 1-55, 1992.
15. Solt DB and Farber E: New principle for the analysis of chemical carcinogenesis. Nature 263: 702-703, 1976.
16. McKenney JM: Lovastatin: a new cholesterol-lowering agent. Clin Pharm 7(1): 21-36, 1988.
17. Inman SR, Stowe NT, Cressman MD, Brouhard BH, Nally JV Jr, Satoh S, Satodate R and Vidt DG: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 317(4): 215-221, 1999. (Pubitemid 30349695)
18. Low P, Andersson M, Edlund C and Dallner G: Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta 1165(1): 102-109, 1992.
19. Stal P, Hultcrantz R, Moller L and Eriksson LC: The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis. Hepatology 21(2): 521-528, 1995.
20. Bjorkhem-Bergman L, Torndal UB, Eken S, Nystrom C, Capitanio A, Larsen EH, Bjornstedt M and Eriksson LC: Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis 26(1): 125-131, 2005.
21. Harms G, van Goor H, Koudstaal J, de Ley L and Hardonk MJ: Immunohistochemical demonstration of DNA-incorporated 5-bromodeoxyuridine in frozen and plastic-embedded sections. Histochemistry 85(2): 139-143, 1986. (Pubitemid 16095198)
22. Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119(3): 493-501, 1992.
23. Acimovic J, Lovgren-Sandblom A, Monostory K, Rozman D, Golicnik M, Lutjohann D and Bjorkhem I: Combined gas chromatographic/mass spectrometric analysis of cholesterol precursors and plant sterols in cultured cells. J Chromatogr B Analyt Technol Biomed Life Sci 877(22): 2081-2086, 2009.
24. Lund E, Sisfontes L, Reihner E and Bjorkhem I: Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 49(2): 165-171, 1989. (Pubitemid 19112173)
25. Wang GS, Olsson JM, Eriksson LC and Stal P: Diet restriction increases ubiquinone contents and inhibits progression of hepatocellular carcinoma in the rat. Scand J Gastroenterol 35(1): 83-89, 2000.
26. Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi C, Watanabe Y and Fujii S: CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 877(1): 50-60, 1986.